{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T17:47:03Z","timestamp":1703094423945},"reference-count":99,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"crossref","award":["7036-01"],"award-info":[{"award-number":["7036-01"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH grants","award":["HL082978-01","CA04963920A2"],"award-info":[{"award-number":["HL082978-01","CA04963920A2"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.leukres.2011.09.018","type":"journal-article","created":{"date-parts":[[2011,10,16]],"date-time":"2011-10-16T09:43:51Z","timestamp":1318758231000},"page":"253-261","source":"Crossref","is-referenced-by-count":12,"title":["What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?"],"prefix":"10.1016","volume":"36","author":[{"given":"Michael W.","family":"Deininger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Manley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2011.09.018_bib0005","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrd892","article-title":"The druggable genome","volume":"1","author":"Hopkins","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.leukres.2011.09.018_bib0010","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.09.018_bib0015","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.09.018_bib0020","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.hoc.2004.03.008","article-title":"Biology of chronic myelogenous leukemia\u2014signaling pathways of initiation and transformation","volume":"18","author":"Melo","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.leukres.2011.09.018_bib0025","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.leukres.2011.09.018_bib0030","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.hoc.2004.03.011","article-title":"Natural history and staging of chronic myelogenous leukemia","volume":"18","author":"Cortes","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.leukres.2011.09.018_bib0035","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2011.09.018_bib0040","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.018_bib0045","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","article-title":"Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells","volume":"23","author":"Remsing Rix","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.09.018_bib0050","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2011.09.018_bib0055","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2011.09.018_bib0060","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2011.09.018_bib0065","doi-asserted-by":"crossref","first-page":"18292","DOI":"10.1074\/jbc.M801337200","article-title":"Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib\/nilotinib and dasatinib","volume":"283","author":"Vajpai","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2011.09.018_bib0070","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2011.09.018_bib0075","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2011.09.018_bib0080","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2011.09.018_bib0085","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2011.09.018_bib0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbapap.2005.07.040","article-title":"Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia","volume":"1754","author":"Manley","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.leukres.2011.09.018_bib0095","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotnib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.09.018_bib0100","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1200\/JCO.2009.26.4945","article-title":"Comparative in vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia","volume":"28","author":"Laneuville","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.09.018_bib0105","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cncr.11863","article-title":"The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase","volume":"100","author":"Sneed","year":"2004","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.leukres.2011.09.018_bib0110","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1182\/blood.V116.21.208.208","article-title":"An ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia","volume":"116","author":"Gambacorti-Passerini","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.018_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/excr.1999.4732","article-title":"Src family tyrosine kinases and growth factor signaling","volume":"254","author":"Abram","year":"2000","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.leukres.2011.09.018_bib0120","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1084\/jem.188.5.833","article-title":"Independent and opposing roles for Btk and lyn in B and myeloid signaling pathways","volume":"188","author":"Satterthwaite","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.leukres.2011.09.018_bib0125","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/ni893","article-title":"Essential role of Src-family protein tyrosine kinases in NF-kappaB activation during B cell development","volume":"4","author":"Saijo","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.leukres.2011.09.018_bib0130","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1182\/blood-2003-12-4396","article-title":"Perturbed myelo\/erythropoiesis in Lyn-deficient mice is similar to that in mice lacking the inhibitory phosphatases SHP-1 and SHIP-1","volume":"104","author":"Harder","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.018_bib0135","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2011.09.018_bib0140","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive CML patients with resistance or intolerance to imatinib","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.018_bib0145","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1526-4610.2011.01929.x","article-title":"Chemical mediators of migraine: preclinical and clinical observations","volume":"51","author":"Gupta","year":"2011","journal-title":"Headache"},{"issue":"Suppl. 10","key":"10.1016\/j.leukres.2011.09.018_bib0150","article-title":"Safety, pharmacokinetics, and pharmacodynamics of PD-0360324, a human monoclonal antibody to monocyte\/macrophage colony stimulating factor, in healthy volunteers","volume":"60","author":"Sadis","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.leukres.2011.09.018_bib0155","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.1016\/j.bmc.2010.08.026","article-title":"Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib","volume":"18","author":"Manley","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.leukres.2011.09.018_bib0160","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.taap.2009.12.032","article-title":"The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity","volume":"244","author":"Hasinoff","year":"2010","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.leukres.2011.09.018_bib0165","series-title":"Tasigna [package insert]","year":"2010"},{"key":"10.1016\/j.leukres.2011.09.018_bib0170","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2011.09.018_bib0175","series-title":"NCI common terminology criteria for adverse events (CTCAE), version 4","year":"2010"},{"key":"10.1016\/j.leukres.2011.09.018_bib0180","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.cellbio.13.1.513","article-title":"Cellular functions regulated by Src family kinases","volume":"13","author":"Thomas","year":"1997","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1016\/j.leukres.2011.09.018_bib0185","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cytogfr.2004.03.002","article-title":"PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma","volume":"15","author":"Ostman","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.leukres.2011.09.018_bib0190","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200705-715CR","article-title":"Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series","volume":"176","author":"Bergeron","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"21","key":"10.1016\/j.leukres.2011.09.018_bib0195","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1182\/blood.V116.21.358.358","article-title":"Lymphocytosis following first-line treatment for CML in chronic phase with dasatinib is associated with improved responses: a comparison with imatinib","volume":"116","author":"Schiffer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.018_bib0200","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":"Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis","volume":"141","author":"de Lavallade","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2011.09.018_bib0205","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/0952-7915(94)90115-5","article-title":"Role of tyrosine kinases in lymphocyte activation","volume":"6","author":"Sefton","year":"1994","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.leukres.2011.09.018_bib0210","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.018_bib0215","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2008-02-138701","article-title":"Dasatinib suppresses in vitro natural killer cell cytotoxicity","volume":"111","author":"Blake","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.018_bib0220","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.09.018_bib0225","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1600-0609.2010.01501.x","article-title":"Immunoprofiling of chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy","volume":"85","author":"Rohon","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2011.09.018_bib0230","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2362.2009.02206.x","article-title":"Immunosuppression and atypical infections in CML patients treated with dasatinib at 140mg daily","volume":"39","author":"Sillaber","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.leukres.2011.09.018_bib0235","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s12185-010-0565-1","article-title":"Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion","volume":"91","author":"Nagata","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.leukres.2011.09.018_bib0240","series-title":"Gleevec [package insert]","year":"2011"},{"key":"10.1016\/j.leukres.2011.09.018_bib0245","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","article-title":"Practical management of patients with chronic myeloid leukemia receiving imatinib","volume":"21","author":"Deininger","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.09.018_bib0250","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejphar.2006.06.068","article-title":"Imatinib inhibits spontaneous rhythmic contractions of human uterus and intestine","volume":"546","author":"Popescu","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.leukres.2011.09.018_bib0255","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.018_bib0260","series-title":"Sprycel [package insert]","year":"2010"},{"key":"10.1016\/j.leukres.2011.09.018_bib0265","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2011.09.018_bib0270","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","article-title":"Long-term imatinib therapy promotes bone formation in CML patients","volume":"111","author":"Fitter","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.018_bib0275","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1359\/jbmr.070719","article-title":"Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms","volume":"22","author":"O'Sullivan","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.leukres.2011.09.018_bib0280","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3324\/haematol.2009.008359","article-title":"Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib","volume":"94","author":"Schmid","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2011.09.018_bib0285","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0140-6736(08)61023-5","article-title":"Low bone density and decreased inhibin-B\/FSH ratio in a boy treated with imatinib during puberty","volume":"372","author":"Mariani","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2011.09.018_bib0290","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.12373","article-title":"Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia","volume":"93","author":"J\u00f6nsson","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2011.09.018_bib0295","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2009-08-237404","article-title":"Dysregulation of bone remodeling by imatinib mesylate","volume":"115","author":"Vandyke","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.018_bib0300","article-title":"Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors","author":"Tibullo","year":"2011","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.leukres.2011.09.018_bib0305","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/jbmr.85","article-title":"The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo","volume":"25","author":"Vandyke","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.leukres.2011.09.018_bib0310","article-title":"Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice","author":"Agostino","year":"2010","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.leukres.2011.09.018_bib0315","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1210\/jc.2010-0086","article-title":"Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?","volume":"95","author":"Fitter","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.leukres.2011.09.018_bib0320","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1056\/NEJM200503103521023","article-title":"Imatinib and regression of type 2 diabetes","volume":"352","author":"Veneri","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2011.09.018_bib0325","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4158\/EP.13.2.126","article-title":"Imatinib and type 2 diabetes","volume":"13","author":"Dingli","year":"2007","journal-title":"Endocr Pract"},{"issue":"21","key":"10.1016\/j.leukres.2011.09.018_bib0330","first-page":"1405","article-title":"Efficacy and safety of nilotinib in chronic phase (CP) chronic myeloid leukemia (CML) patients (pts) with type 2 diabetes in the ENESTnd trial","volume":"116","author":"Saglio","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.018_bib0335","doi-asserted-by":"crossref","first-page":"18895","DOI":"10.1073\/pnas.0810246105","article-title":"Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice","volume":"105","author":"Louvet","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.leukres.2011.09.018_bib0340","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2337\/db08-0080","article-title":"Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db\/db mice","volume":"58","author":"Han","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.leukres.2011.09.018_bib0345","doi-asserted-by":"crossref","first-page":"37747","DOI":"10.1074\/jbc.M105796200","article-title":"Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells","volume":"276","author":"Boren","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2011.09.018_bib0350","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1038\/sj.onc.1208461","article-title":"Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation","volume":"24","author":"Barnes","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2011.09.018_bib0355","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/sj.leu.2404827","article-title":"UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia","volume":"21","author":"Singer","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.09.018_bib0360","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","article-title":"Dermatologic side effects associated with the epidermal growth factor receptor inhibitors","volume":"55","author":"Agero","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.leukres.2011.09.018_bib0365","first-page":"215","article-title":"Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors","volume":"2","author":"Huang","year":"2008","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.leukres.2011.09.018_bib0370","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-06-2610","article-title":"Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies","volume":"13","author":"Wacker","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2011.09.018_bib0375","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1634\/theoncologist.9-3-271","article-title":"Indications for imatinib mesylate therapy and clinical management","volume":"9","author":"Guilhot","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.leukres.2011.09.018_bib0380","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1002\/cncr.11812","article-title":"Imatinib mesylate causes hypopigmentation in the skin","volume":"98","author":"Tsao","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2011.09.018_bib0385","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S1658-3876(09)50026-X","article-title":"Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia","volume":"2","author":"Aleem","year":"2009","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.leukres.2011.09.018_bib0390","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1365-4632.2004.02114.x","article-title":"Piebaldism: an update","volume":"43","author":"Thomas","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.leukres.2011.09.018_bib0395","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1073\/pnas.0913131107","article-title":"c-Abl tyrosine kinase regulates cardiac growth and development","volume":"107","author":"Qiu","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.leukres.2011.09.018_bib0400","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkel\u00e4","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.leukres.2011.09.018_bib0405","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.leukres.2010.01.004","article-title":"Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies","volume":"34","author":"Wolf","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2011.09.018_bib0410","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.leukres.2010.11.001","article-title":"Preclinical evaluation of potential nilotinib cardiotoxicity","volume":"35","author":"Wolf","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2011.09.018_bib0415","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2007-01-070144","article-title":"Congestive heart failure is a rare event in patients receiving imatinib therapy","volume":"110","author":"Atallah","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.018_bib0420","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ajh.21157","article-title":"Brain natriuretic peptide level as marker of cardiac function in imatinib-treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy","volume":"83","author":"Tiribelli","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2011.09.018_bib0425","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.leukres.2008.03.020","article-title":"An evaluation of the cardiotoxicity of imatinib mesylate","volume":"32","author":"Ribeiro","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2011.09.018_bib0430","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ejca.2007.01.018","article-title":"Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005","volume":"43","author":"Verweij","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.leukres.2011.09.018_bib0435","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/blood-2008-09-180604","article-title":"Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia","volume":"114","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.018_bib0440","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1002\/cncr.24257","article-title":"Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy","volume":"115","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2011.09.018_bib0445","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1083\/jcb.200208043","article-title":"Integrin alpha2beta1 mediates outside-in regulation of platelet spreading on collagen through activation of Src kinases and PLCgamma2","volume":"160","author":"Inoue","year":"2003","journal-title":"J Cell Biol"},{"key":"10.1016\/j.leukres.2011.09.018_bib0450","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1096\/fj.04-1940fje","article-title":"Adhesion of human and mouse platelets to collagen under shear: a unifying model","volume":"19","author":"Auger","year":"2005","journal-title":"FASEB J"},{"key":"10.1016\/j.leukres.2011.09.018_bib0455","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.018_bib0460","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.208","article-title":"Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib","volume":"87","author":"Tanaka","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.leukres.2011.09.018_bib0465","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1365-2125.2008.03150.x","article-title":"Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia","volume":"65","author":"Wang","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.leukres.2011.09.018_bib0470","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.018_bib0475","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.018_bib0480","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","article-title":"Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications","volume":"14","author":"Hiwase","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2011.09.018_bib0485","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.leukres.2011.09.018_bib0490","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nbt1328","article-title":"Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors","volume":"25","author":"Bantscheff","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"18S","key":"10.1016\/j.leukres.2011.09.018_bib0495","first-page":"953s","article-title":"Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study","volume":"28","author":"Kantarjian","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611004619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611004619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T04:40:03Z","timestamp":1639197603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212611004619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":99,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0145212611004619"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2011.09.018","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}